Current stock page

Financial Data

MAZE Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MAZEMaze Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$34.33−$1.76 (−4.88%)

Latest quote

  • Momentum
    83
  • Value
    42
  • Quality
    50
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$20M$0$0$0$0$0
Gross Profit$0$0$19.56M-$499K$0-$649K$0$0
Operating Income-$51.52M-$48.04M-$26.55M-$38.06M-$32.97M-$36.47M-$35.4M-$29.73M
Net Income-$47.97M-$44.73M-$24.21M-$34.57M-$30.09M-$33.68M-$32.79M-$29.58M
EPS-$0.79-$0.76-$0.45-$0.87-$0.66-$0.77-$0.75-$0.11
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$32.84M-$15.05M-$39.11M-$27.73M-$24.64M-$30.05M-$29.52M-$22.45M
Capital Expenditure-$288K-$107K-$93K-$34K-$68K-$393K-$299K-$605K
Free Cash Flow-$33.13M-$15.16M-$39.21M-$27.76M-$24.71M-$30.45M-$29.82M-$23.06M
Net Cash Provided By Operating Activities-$32.84M-$15.05M-$39.11M-$27.73M-$24.64M-$30.05M-$29.52M-$22.45M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$511.56M$531.63M$419.71M$397.13M$422.06M$303.52M$332.84M$240.54M
Total Debt$59.64M$60.42M$61.22M$23.31M$24.18M$25.01M$25.82M$26.63M
Cash And Cash Equivalents$154.16M$202.64M$198.77M$189.25M$316.77M$264.54M$294.37M$196.81M
Total Liabilities$83.01M$78.5M$78.01M$42.16M$42.62M$41.28M$40.77M$43.64M
Total Stockholders Equity$428.55M$453.12M$341.7M$354.97M$379.44M$262.24M$292.07M$196.9M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.963.564.073.843.57———
P/S ratio104.47———————
Debt To Equity0.140.130.180.070.060.10.090.14
Free Cash Flow Yield-5.42%-6.63%-8.79%-8.27%-7.96%———
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.963.564.073.843.57———
P/S ratio104.47———————
Return On Equity-35.35%-29.48%-35.86%-36.94%-33.24%-46.06%17.78%26.53%
Debt To Equity0.140.130.180.070.060.10.090.14

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-11.96x
Pb4.88x
EPS Growth Yoy-19.70%
Gross Margin95.28%
Operating Margin-820.82%
ROE-38.39%
ROIC-33.63%
Debt To Equity0.14
FCF Yield-6.14%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$34.33
Volume1.37M
RSI (14)60.26
MACD1.92
MACD signal1.72
MACD histogram0.2
ADX (14)31.98
SMA (50)$28.68
SMA (200)$31.37
ATR (14)$1.86
Historical volatility (annualized)61.08%
Volume (20-day average)702,330

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score47/100
Beta0.75
Annual volatility67.20%
Max Drawdown-56.81%
Sharpe Ratio0.41
VaR (95%, 1-day)-4.48%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MAZE Financial Data FAQ

What is Maze Therapeutics, Inc.'s revenue?

Maze Therapeutics, Inc.'s revenue is one of the core financial data points for MAZE. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Maze Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Maze Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MAZE's EPS?

MAZE's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Maze Therapeutics, Inc.'s net income?

Maze Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Maze Therapeutics, Inc. generate?

Free cash flow shows how much cash Maze Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Maze Therapeutics, Inc. have?

Cash and debt help frame MAZE's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.